By Richard Lenti
Good news for people suffering from multiple sclerosis. The results of a long term study show that Tecfidera, the newest multiple sclerosis (MS) drug on the market, remained effective for patients taking the medicine for at least four years with no new safety problems.
The news is also good for the drug’s manufacturer, Massachusetts-based Biogen Idec (NASDAQ: BIIB). Analyst expect sales of the twice-a-day dimethyl fumarate capsules (sold under the brand name Tecfidera) to eventually dominate the MS market.
In its first quarter on the market, the drug had sales of $192 million, nearly triple Wall Street expectations. Biogen has a 15-year patent on the drug, which costs patients over $4,000 a month.
“Because MS is a chronic, life-long disease, physicians and patients need to know they are taking a treatment that will offer them sustained efficacy over the long-term with a consistent safety profile,” said Doug Williams, executive vice president, Research and Development, Biogen Idec.
“These analyses provide important information on the benefits of Tecfidera’s strong efficacy and favorable safety for a wide range of patients.”
Read more at National Pain Report.
(0) Readers Comments
November 12, 2012
October 08, 2012
September 12, 2012
July 23, 2012
June 11, 2019
April 01, 2019
March 18, 2019
Oh boy...Your right we hate to hear this. You know why people in pain
Doesn't the 1.5 billion is spent a year give credence to its possitive
Many MS drugs cause PML and deaths too these drugs all need t
I knew him when he was breaking in at a couple of Los Angeles TV stati
Saying there is a 'twist' is the worst type of spoile